Analytical Data
-
Gene name
HLA-DRA1*01:01&DRB1*11:01&Influenza HA (PKYVKQNTLKLAT) Monomer
- Application
-
Alternative Names
HLA-DRA1*0101 & HLA-DRB1*1101 & Influenza HA (PKYVKQNTLKLAT)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
CAI2388006.1 (I26-E216)&CAI2388099.1
-
Expression Region
CAI2388006.1 (I26-E216)&CAI2388099.1 (G30-K227)&PKYVKQNTLKLAT
-
Molecular Weight
38-42 kDa and 35-36 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-DRA1*01:01 and DRB1*11:01 are key components of the human Major Histocompatibility Complex (MHC) Class II molecules, which play a crucial role in the adaptive immune response by presenting processed peptides to CD4+ T cells. The specific investigation of the influenza hemagglutinin (HA) peptide PKYVKQNTLKLAT, derived from the influenza virus, is significant due to its importance in eliciting immune responses, particularly in the context of vaccine development. This monomeric recombinant protein serves as a model to understand the molecular interactions between HLA Class II molecules and viral peptides. By studying the binding affinity and stability of this peptide within the HLA-DRA1*01:01/DRB1*11:01 complex, researchers aim to elucidate the epitopes recognized by the immune system during influenza infections or vaccinations. Insights gained from this research can aid in the design of more effective vaccines and immunotherapies, particularly by targeting specific MHC-peptide interactions that are pivotal for T cell activation and memory formation. Furthermore, understanding how certain alleles, like DRB1*11:01, may influence immune responses to influenza can provide valuable information on population-specific susceptibility to infections and help in tailoring public health strategies.
